|
BPTF |
bromodomain PHD finger transcription factor |
|
|
|
|
C2orf68 |
chromosome 2 open reading frame 68 |
|
|
|
|
CARD10 |
caspase recruitment domain family member 10 |
|
|
|
|
CAT |
catalase |
- Detoxification of Reactive Oxygen Species
- Neutrophil degranulation
- Peroxisomal protein import
- Peroxisomal protein import
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
|
- Fomepizole
- Cannabidiol
- Medical Cannabis
- Nabiximols
|
- Acatalasia, including: Acatalasemia; Takahara's disease; Hypocatalasemia
|
|
CCNB1IP1 |
cyclin B1 interacting protein 1 |
|
|
|
|
CDH1 |
cadherin 1 |
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Integrin cell surface interactions
- Apoptotic cleavage of cell adhesion proteins
- Adherens junctions interactions
- RHO GTPases activate IQGAPs
- InlA-mediated entry of Listeria monocytogenes into host cells
|
|
- Gastric cancer
- Penile cancer
- Nasopharyngeal cancer
- Breast cancer
- Hepatocellular carcinoma
- Thyroid cancer
|
|
CDK6 |
cyclin dependent kinase 6 |
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Cyclin D associated events in G1
- Regulation of RUNX1 Expression and Activity
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
|
- Alvocidib
- (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
- Fisetin
- Palbociclib
- Ribociclib
- Abemaciclib
|
|
|
CLU |
clusterin |
- Platelet degranulation
- Terminal pathway of complement
- Antimicrobial peptides
- Regulation of Complement cascade
|
- Zinc
- Copper
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
COL1A1 |
collagen type I alpha 1 chain |
- GPVI-mediated activation cascade
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Assembly of collagen fibrils and other multimeric structures
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- ECM proteoglycans
- Scavenging by Class A Receptors
- GP1b-IX-V activation signalling
- Platelet Adhesion to exposed collagen
- Platelet Adhesion to exposed collagen
- Platelet Aggregation (Plug Formation)
- MET activates PTK2 signaling
- RUNX2 regulates osteoblast differentiation
- Collagen chain trimerization
|
- Collagenase clostridium histolyticum
- Halofuginone
- Clove oil
- Vonicog Alfa
- Von Willebrand Factor Human
|
- Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
- Infantile cortical hyperostosis; Caffey disease
- Osteogenesis imperfecta
|
|
COL2A1 |
collagen type II alpha 1 chain |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Signaling by PDGF
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- ECM proteoglycans
- NCAM1 interactions
- MET activates PTK2 signaling
- Collagen chain trimerization
|
- Collagenase clostridium histolyticum
|
- Type II collagenopathies, including: Achondrogenesis II; Hypochondrogenesis; SED congenita; SMED Strudwick type; Kniest dysplasia; Spondyloperipheral dysplasia; Osteoarthritis with mild chondrodysplasia; Stickler syndrome 1; Platyspondylic skeletal dysplasia, Torrance type; Epiphyseal dysplasia, multiple, with myopia and deafness; Czech dysplasia
- Vitreoretinal degeneration, including: Stickler syndrome type I (STL1); Stickler syndrome type II (STL2); Snowflake vitreoretinal degeneration (SVD); Wagner syndrome 1 (WGN1); Knobloch syndrome (KNO); Enhanced S-cone syndrome (ESCS); Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
- Osteoarthritis with mild chondrodysplasia
|
|
CPEB2 |
cytoplasmic polyadenylation element binding protein 2 |
|
|
|
|
CSNK2A1 |
casein kinase 2 alpha 1 |
- Synthesis of PC
- WNT mediated activation of DVL
- Condensation of Prometaphase Chromosomes
- Signal transduction by L1
- Regulation of TP53 Activity through Phosphorylation
- Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
- Receptor Mediated Mitophagy
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of PTEN stability and activity
|
- ATP
- (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Quercetin
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- Emodin
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- Dichlororibofuranosylbenzimidazole
- Quinalizarin
- Ellagic acid
- Fostamatinib
|
|
|
CTTN |
cortactin |
- RHO GTPases activate PAKs
- Clathrin-mediated endocytosis
|
|
|
|
CUL3 |
cullin 3 |
- Degradation of DVL
- Hedgehog 'on' state
- Regulation of RAS by GAPs
- Neddylation
- RHOBTB2 GTPase cycle
- RHOBTB1 GTPase cycle
- RHOBTB3 ATPase cycle
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
DPP3 |
dipeptidyl peptidase 3 |
|
|
|
|
EAF1 |
ELL associated factor 1 |
- Formation of RNA Pol II elongation complex
- RNA Polymerase II Pre-transcription Events
- RNA Polymerase II Transcription Elongation
|
|
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|
|
ERICH5 |
glutamate rich 5 |
|
|
|
|
ETF1 |
eukaryotic translation termination factor 1 |
- Eukaryotic Translation Termination
- Eukaryotic Translation Termination
- Regulation of expression of SLITs and ROBOs
- Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
|
|
|
|
FAM117B |
family with sequence similarity 117 member B |
|
|
|